Antiangiogenic agents in the treatment of prostate cancer

Prostate cancer remains the most commonly diagnosed noncutaneous malignancy among men in the United States. Once prostate cancer becomes metastatic, there is no curative therapy. Angiogenesis, the process of new blood vessel formation, plays a central role in prostate cancer growth and metastasis and angiogenic markers have been shown to correlate with prostate cancer prognosis. Several therapeutic strategies targeting angiogenesis in prostate cancer have been undertaken and will be reviewed here.